These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 7003128)

  • 1. Chemotherapy of the myeloid leukaemias.
    Stuart J
    J R Coll Physicians Lond; 1980 Jan; 14(1):36-41. PubMed ID: 7003128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative trial of remission induction (by cytosine arabinoside, or C.A.R. and thioguanine, or C.A.R. and daunorubicine) and maintenance therapy (by C.A.R. or methylgag) in acute myeloid leukaemia.
    Biomedicine; 1973 May; 18(3):192-8. PubMed ID: 4517790
    [No Abstract]   [Full Text] [Related]  

  • 3. Intensive chemotherapy for acute myelogenous leukemia.
    Gale RP; Foon KA; Cline MJ; Zighelboim J
    Ann Intern Med; 1981 Jun; 94(6):753-7. PubMed ID: 6940466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D.A.T. (daunorubicin, cytarabine, 6-thioguanine) in acute myeloid leukaemia.
    Rees JK; Hayhoe FG
    Lancet; 1978 Jun; 1(8078):1360-1. PubMed ID: 78123
    [No Abstract]   [Full Text] [Related]  

  • 5. Progress in acute myelogenous leukemia.
    Gale RP
    Cancer Treat Rep; 1981; 65 Suppl 4():87-92. PubMed ID: 7049383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High remission-induction rate in acute myeloid leukaemia.
    Gale RP; Cline MJ
    Lancet; 1977 Mar; 1(8010):497-9. PubMed ID: 65605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute myelogenous leukemia: morphologic classification and response to therapy.
    Foon KA; Naiem F; Yale C; Gale RP
    Leuk Res; 1979; 3(3):171-3. PubMed ID: 288959
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of thioguanine on a combination of daunorubicine, cytarabine and prednisone in the treatment of acute leukaemia in adults. The Finnish Leukaemia Group.
    Scand J Haematol; 1979 Aug; 23(2):124-8. PubMed ID: 291122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemia.
    Wiernik PH; Glidewell OJ; Hoagland HC; Brunner KW; Spurr CL; Cuttner J; Silver RT; Carey RW; DelDuca V; Kung FH; Holland JF
    Med Pediatr Oncol; 1979; 6(3):261-77. PubMed ID: 381887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of the effects of cytosine arabinoside, cytosine arabinoside and thioguanine, and cytosine arabinoside and daunorubicin in acute myeloid leukemia].
    Malpas J; Mathé G; Hayat M
    Bull Cancer; 1974; 61(3):411-8. PubMed ID: 4533741
    [No Abstract]   [Full Text] [Related]  

  • 11. The treatment of acute myeliod leukaemia.
    Friend JH; Giles C; Richardson SG
    J Clin Pathol; 1974 Jan; 27(1):53-4. PubMed ID: 4522738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A second comparative trial of remission induction (by cytosine arabinoside given every 12 hours, or C.A.R. and thioguanine, or C.A.R. and daunorubicine) and maintenance therapy (by C.A.R. or methylgag) in acute myeloid leukaemia.
    Eur J Cancer (1965); 1974 Jul; 10(7):413-8. PubMed ID: 4532961
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
    Berman E; Arlin ZA; Gaynor J; Miller W; Gee T; Kempin SJ; Mertelsmann R; Andreeff M; Reich L; Nahmias N
    Leukemia; 1989 Feb; 3(2):115-21. PubMed ID: 2911205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two years' experience in the treatment of acute myeloid leukaemia using a three-drug regimen: daunorubicin, cytosine arabinoside and 6-thioguanine.
    McCann SR; Lawlor E; Kinsella IA; Temperley IJ
    Ir Med J; 1982 Nov; 75(11):415-7. PubMed ID: 6959984
    [No Abstract]   [Full Text] [Related]  

  • 15. Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941.
    Lange BJ; Dinndorf P; Smith FO; Arndt C; Barnard D; Feig S; Feusner J; Seibel N; Weiman M; Aplenc R; Gerbing R; Alonzo TA
    J Clin Oncol; 2004 Jan; 22(1):150-6. PubMed ID: 14701777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of advanced myelodysplastic syndromes: trend toward more aggressive chemotherapy?
    Aul C; Schneider W
    Haematol Blood Transfus; 1990; 33():382-6. PubMed ID: 2323646
    [No Abstract]   [Full Text] [Related]  

  • 17. The impact of early intensive therapy on event-free survival (EFS) in children with acute myeloid leukemia (AML).
    Weinstein H; Ravindranath Y; Krischer J; Steuber P; Civin C; Gresik M; Vietti T
    Leukemia; 1992; 6 Suppl 2():52-4. PubMed ID: 1578941
    [No Abstract]   [Full Text] [Related]  

  • 18. Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML8 B). The EORTC Leukemia Cooperative Group and the GIMEMA Group.
    Zittoun R; Liso V; Mandelli F; Rotoli B; de Witte T; Gattringer C; Resegotti L; Caronia F; Leoni P; Petti MC
    Leukemia; 1992; 6 Suppl 2():76-7. PubMed ID: 1578949
    [No Abstract]   [Full Text] [Related]  

  • 19. The nature of remission in acute myeloblastic leukaemia.
    Powles RL; Selby PJ; Palu G; Morgenstern G; McElwain TJ; Clink HM; Alexander P
    Lancet; 1979 Sep; 2(8144):674-6. PubMed ID: 90762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial.
    Archimbaud E; Fiere D; Treille-Ritouet D; Adeleine P; Guyotat D; Sebban C; Vuvan H; Viala JJ
    Cancer Treat Rep; 1987 Jun; 71(6):571-4. PubMed ID: 3555788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.